KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Gains from Investment Securities (2016 - 2025)

Abbott Laboratories' Gains from Investment Securities history spans 17 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 14.53% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $1.9 billion, up 12.19%, while the annual FY2025 figure was $1.9 billion, 12.19% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $2.0 billion at Abbott Laboratories, up from -$90.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.0 billion in Q4 2025 and bottomed at -$90.0 million in Q3 2025.
  • The 5-year median for Gains from Investment Securities is -$2.0 million (2022), against an average of $352.2 million.
  • The largest annual shift saw Gains from Investment Securities surged 17975.0% in 2023 before it plummeted 4400.0% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $1.9 billion in 2021, then crashed by 100.42% to -$8.0 million in 2022, then soared by 17975.0% to $1.4 billion in 2023, then grew by 20.84% to $1.7 billion in 2024, then grew by 14.53% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Gains from Investment Securities are $2.0 billion (Q4 2025), -$90.0 million (Q3 2025), and $52.0 million (Q2 2025).